This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Acorda Therapeutics Receives Silver Awards From Medical Marketing & Media Magazine For Consumer Website And AMPYRA Healthcare Professional Print Campaign

Stocks in this article: ACOR

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the Company received two Silver Awards at the annual Medical Marketing & Media (MM&M) Awards ceremony: one for its Consumer site in the category of Best Branded Website, and a second for its AMPYRA healthcare professional campaign in the Best Professional Print Campaign category. The MM&M Awards recognize exceptional creativity and marketing effectiveness among all companies in the pharmaceutical and biotechnology industries. There are 24 categories of awards and only a Gold and Silver Award are presented for each category. This year was especially competitive with two comprehensive rounds of scoring by more than 100 independent industry judges, representing a wide variety of backgrounds in healthcare.

“It is an honor to have been recognized by our peers in the industry for our innovative consumer and health care professional communications,” said Lauren Sabella, Acorda’s Executive Vice President, Commercial Development. “These awards are a testament to the passion and commitment of Acorda’s employees to making a positive difference in the lives of people with MS. Our goal is to increase awareness of important information about MS and AMPYRA, helping to facilitate educated dialogue between physicians and consumers about their healthcare decisions.”

In addition to being recognized by MM&M, in 2012 Acorda has also been awarded the PM360 Trailblazer Award for best health care professional advertising campaign, as well as Gold and Silver W3 Awards from the International Academy of the Visual Arts for The Company also received two Telly Awards this year for online video production and editing.

AMPYRA is approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with MS. This was demonstrated by an improvement in walking speed.

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs